|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Du145 and PC3, two cell lines from advanced metastatic prostate cancer, which are characterized as androgen-independent and -insensitive, did not express AR but expressed a high level of WT1.
|
11299720 |
2001 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
|
19257827 |
2009 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that there was a significant correlation between MMP9 and AR protein expression in primary and metastatic PCa tissues, and a trend that high level of MMP9 expression was associated with poor prognosis.
|
31381135 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgen-independent metastatic prostate cancer is characterized by a heterogeneous loss of androgen receptor (AR) expression among tumor cells.
|
9850055 |
1998 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Adaptive resistance of metastatic prostate cancer to enzalutamide treatment can be due to the activation of both androgen receptor (AR)-dependent pathways (expression of constitutively active AR splice variants, AR point mutations, gene amplification and overexpression) and mechanisms independent of AR signaling pathway (altered steroidogenesis, upregulation of the glucocorticoid receptor, epithelial-mesenchymal transition, neuroendocrine transformation, autophagy and activation of the immune system).
|
30425524 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
|
21799031 |
2011 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used probe combinations that included the androgen receptor (AR) and MYC genes for FISH analysis of CTC samples collected from 77 men with castration-resistant metastatic prostate cancer.
|
19276271 |
2009 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As second-generation androgen receptor antagonists have been increasingly used for treatment of castration-resistant stage metastatic prostate cancer, new onset of symptomatic epidural lipomatosis should be considered as a possible differential diagnosis, especially because the urinary symptoms of cauda equina compression may be improperly attributed to the primary prostate neoplasm.
|
30763756 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
|
26364608 |
2016 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two features of the progression from organ-confined to metastatic prostate cancer are dysregulation of the androgen receptor (AR) and a decrease in insulin-like growth factor-type-I receptor (IGF-IR) expression.
|
15368471 |
2004 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC).
|
29017058 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel AR signaling pathway that induces microRNA-1 (miR-1) to suppress metastatic prostate cancer was recently demonstrated (AR-miR-1 signaling axis), and its regulation of Wnt signaling was explored in the current study.
|
28220803 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
|
15774258 |
2005 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed outcomes in men with low prostate specific antigen and a high disease burden who received the oral androgen receptor inhibitor enzalutamide in the PREVAIL (Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer) study.
|
28736322 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
|
27733296 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively.
|
22767266 |
2012 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors usually develop resistance (castration-resistant PCa [CRPC]), but remain androgen receptor (AR) dependent.
|
26378018 |
2015 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although potent androgen receptor pathway inhibitors (ARPI) improve overall survival of metastatic prostate cancer patients, treatment-induced neuroendocrine prostate cancer (t-NEPC) as a consequence of the selection pressures of ARPI is becoming a more common clinical issue.
|
28427194 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings showing frequent expression of structurally unaltered androgen receptor in an advanced stage of EMPD may provide a rational basis for hormone therapy, which is widely used in the treatment of metastatic prostate cancer and androgen receptor-positive breast cancer recurrence.
|
11005214 |
2000 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The standard treatment for metastatic prostate cancer, androgen deprivation therapy (ADT), is designed to suppress androgen receptor (AR) activity.
|
30242112 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro reporter assays revealed that the hON-522E promoter is highly active in androgen receptor negative and metastatic prostate cancer and bone stromal cells compared to androgen receptor-positive prostate cancer cells.
|
27054343 |
2016 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies.
|
29530945 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study also highlights that approaches to target advanced PC require intelligent combination of agents to target single/multiple signalling pathways in combination with androgen receptor (AR) blockade.
|
29314004 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that AR, MMP-9 and EGFR are interconnect factors, which may cooperatively promote PCa progression.
|
30134822 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we discuss the current knowledge of mechanisms via which the AR signaling drives therapeutic resistance in prostate cancer metastatic progression and the novel therapeutic interventions targeting AR in CRPC.
|
24948871 |
2014 |